key: cord-0715125-bw0mvv56
authors: Rodriguez del Rio, Pablo; Caimmi, Davide; Rico, Pilar; Vidal, Carmen; Carmen, Moreno; Pintoiu, Ileana M.; Beitia Mazuecos, Jose M.; Gonzalez de Olano, David; Cuesta Alvaro, Pedro; Demoly, Pascal; Calderon, Moises A.
title: Real‐life report of allergen immunotherapy management during the COVID‐19 outbreak in France and Spain
date: 2021-11-15
journal: Clin Exp Allergy
DOI: 10.1111/cea.14043
sha: ad82d6758cf910ab4760726b587adaa8ebb6459e
doc_id: 715125
cord_uid: bw0mvv56

The COVID-19 pandemic represents a global health-crisis and a challenge at all societal, economic and health levels. With the first case having been reported in most of the European countries in January 2020 (1), it was not until March that the pandemic hit the territory and lead to an unprecedent hard lock-down in most countries.

To the editor, The COVID-19 pandemic represents a global health crisis and a challenge at all societal, economic and health levels. With the first cases having been reported in most of the European countries in January 2020, 1 it was not until March that the pandemic hit the territory and lead to an unprecedent hard lock-down in most countries.

In response to the crisis, the scientific society has put tremendous efforts in producing numerous clinical practice guidelines for non-COVID patients. In the field of allergy, 2,3 and more specifically in allergen immunotherapy (AIT), 4 position papers have given recommendations on several aspects of AIT practice for the safety of patients and health care professionals. After 1 year since the beginning of the pandemic, few real-life data have been reported on how AIT has been managed during and post the lockdown periods.

To assess how COVID-19 crisis affected aeroallergen AIT prescription patterns during the lockdown period and the following post peak period, we collected real world data from doctors in Spain and France. We set this survey in the framework of the ongoing academic "CHOICE" (Criteria Used by Health Professionals on the (Figure 1) , and pausing the treatment and changing the administration setting were the two most frequent applied strategies.

Our research provides real-life data showing a significant reduction in the number of respiratory patients referred to allergy specialists, the number of new AIT administered and also changes in qualitative prescription patterns during the first COVID-19 pandemic peak, that only partially recovered after the lockdown.

AIT initiation during the pandemic peak (high community prevalence) has been generally discouraged in guidelines whilst already started treatments were advised to be maintained on the treatment. 2, 6, 7 This trend has been recently supported with real life data from a worldwide survey. 8 

which is a direct sign of the relevance of patient´s involvement in the AIT selection process, as part of precision medicine. 9 For AIT initiation, 27% of SCIT prescribers used SLIT more frequently, a trend that remained stable during the post peak phase. Several authors 10, 11 suggested that SLIT might be more appropriate during the pandemic because of the possibility of home-based administration and of a better safety profile, thus minimizing visits to healthcare facilities.

Although SLIT maintenance treatments experienced nearly no changes, 55.5% of SCIT prescribers applied treatment modifications during lockdown. It has been very recently published 12 that among 183 SCIT prescribers, up to 79%, made changes in their SCIT maintenance patients, and 31% discontinued the treatment if they were in the up-dosing phase. Our cohort reported very few treatment withdrawals, but frequently paused treatments (41.8%), which is comparable with the 72% of participants having increased dosing intervals in the referenced manuscript 12 . 

We are grateful to all physicians for their participation in the survey and generously devoting time and effort to provide their practice data.

Authors declare no conflicts of interest.

All authors have made substantial contributions for the conception and design of the study, the acquisition of data, the analysis and interpretation of data and drafted and/or revised it critically providing their approval to the final version.

The data contained is only related to overall practice of physicians, who voluntarily provided all information. There was no need for ethical committee evaluation. 

(all SLIT prescribers)

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

COVID-19: pandemic contingency planning for the allergy and immunology clinic

COVID-19 pandemic: practical considerations on the organization of an allergy clinic-An EAACI/ ARIA position paper

Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement

Allergen immunotherapy using NPP: Perspectives for the treatment and prevention of respiratory allergies; the case of pollinosis

COVID-19 and allergy: how to take care of allergic patients during a pandemic?

A phased approach to resuming suspended allergy/immunology clinical services

COVID-19 pandemic and allergen immunotherapy -an EAACI survey

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis -A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

Allergen immunotherapy in the era of SARS-CoV-2

An academic allergy unit during COVID-19 pandemic in Italy

Change in allergy practice during the COVID-19 pandemic

The unexpected risks of COVID-19 on asthma control in children

Johns Hopkins Coronavirus Resource Center